Galecto, Inc. (GLTO)
- Previous Close
2.7100 - Open
2.7298 - Bid --
- Ask --
- Day's Range
2.7290 - 2.9500 - 52 Week Range
2.0100 - 17.8750 - Volume
24,715 - Avg. Volume
255,314 - Market Cap (intraday)
3.756M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-18.5300 - Earnings Date May 8, 2025 - May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
galecto.comRecent News: GLTO
View More
Performance Overview: GLTO
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLTO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLTO
View MoreValuation Measures
Market Cap
3.57M
Enterprise Value
-9.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.25
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.15%
Return on Equity (ttm)
-89.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.44M
Diluted EPS (ttm)
-18.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
14.18M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
-10.55M